GAF Healthcare
Specialty Overview

Best Hospitals for Leukemia Treatment in Bengaluru, India

10 hematology hospitals in our India network are listed in Bengaluru, accredited by NABH, JCI, NABL, ISO 9001, with 3,630 beds combined.

10
Hospitals Listed
1
City
4.5
Avg. Rating
4
Accreditation Types
The Short Answer

This page lists the hematology hospitals in our directory offering Leukemia Treatment in Bengaluru, India, including Narayana Health, Manipal Hospitals, Medicover Hospital, Bangalore, Gleneagles Hospitals, Bengaluru and others. Each listing links through to the hospital's full profile page.

Including:🇮🇳 Narayana Health🇮🇳 Manipal Hospitals🇮🇳 Medicover Hospital, Bangalore

Ask us about leukemia treatment in Bengaluru, India

Share a few details and our care coordination team will get back to you with next steps.

Top Hospitals for Leukemia Treatment in Bengaluru, India

Narayana Health Featured

🇮🇳 Narayana Health

Bengaluru, India 4.8 (1750 reviews) 1,000 beds
Why consider this hospital?
4.8/5 rating from 1750 reviews1,000 beds
Specialties & Accreditation
CardiacPediatric SurgeryCancer
NABH — National Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering leukemia treatment can be cared for by Narayana Health's care team in Bengaluru, India, from initial consultation through recovery. Narayana Health, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing leukemia treatment.

4.8/5
Rating
2000
Established
1,000
Beds
Bengaluru, India
Location
Enquire NowView Profile
Manipal Hospitals

🇮🇳 Manipal Hospitals

Bengaluru, India 4.7 (1450 reviews) 600 beds
Why consider this hospital?
4.7/5 rating from 1450 reviews600 beds
Specialties & Accreditation
OrthopedicsNeurologyIVF
JCI — Joint Commission International accreditationNABH — National Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering leukemia treatment can be cared for by Manipal Hospitals's care team in Bengaluru, India, from initial consultation through recovery. Manipal Hospitals, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing leukemia treatment.

4.7/5
Rating
1991
Established
600
Beds
Bengaluru, India
Location
Enquire NowView Profile
Medicover Hospital, Bangalore

🇮🇳 Medicover Hospital, Bangalore

Bengaluru, India 4.7 (68 reviews) 300 beds
Why consider this hospital?
4.7/5 rating from 68 reviews300 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyNeurologyOrthopedicsUrology
NABH — National Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering leukemia treatment can be cared for by Medicover Hospital, Bangalore's care team in Bengaluru, India, from initial consultation through recovery. Medicover Hospital, Bangalore, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing leukemia treatment.

4.7/5
Rating
2024
Established
300
Beds
Bengaluru, India
Location
Enquire NowView Profile
Gleneagles Hospitals, Bengaluru

🇮🇳 Gleneagles Hospitals, Bengaluru

Bengaluru, India 4.7 (142 reviews) 40 beds
Why consider this hospital?
4.7/5 rating from 142 reviews40 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyNeurologyOrthopedicsGastroenterology
NABH — National Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering leukemia treatment can be cared for by Gleneagles Hospitals, Bengaluru's care team in Bengaluru, India, from initial consultation through recovery. Gleneagles Hospitals, Bengaluru, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing leukemia treatment.

4.7/5
Rating
2017
Established
40
Beds
Bengaluru, India
Location
Enquire NowView Profile
Manipal Hospital Malleshwaram (Northside)

🇮🇳 Manipal Hospital Malleshwaram (Northside)

Malleshwaram, Bengaluru, India 4.6 (71 reviews) 83 beds
Why consider this hospital?
4.6/5 rating from 71 reviews83 beds
Specialties & Accreditation
Cardiac SciencesOrthopedicsNeurosciencesGastroenterologyOncology
NABH — National Accreditation Board for Hospitals & Healthcare Providers accreditationNABL — National Accreditation Board for Testing and Calibration Laboratories accreditationISO — ISO 9001 certification

Patients considering leukemia treatment can be cared for by Manipal Hospital Malleshwaram (Northside)'s care team in Malleshwaram, Bengaluru, India, from initial consultation through recovery. Manipal Hospital Malleshwaram (Northside), accredited by NABH, NABL, ISO 9001, follows recognised patient-safety and quality-of-care standards when performing leukemia treatment.

4.6/5
Rating
1993
Established
83
Beds
Malleshwaram, Bengaluru, India
Location
Enquire NowView Profile
Manipal Hospital, Old Airport Road

🇮🇳 Manipal Hospital, Old Airport Road

Bangalore, India 4.5 (87 reviews) 680 beds
Why consider this hospital?
4.5/5 rating from 87 reviews680 beds
Specialties & Accreditation
Cardiac SurgeryNeurosciencesTransplantOncologyOrthopedics
NABH — National Accreditation Board for Hospitals & Healthcare Providers accreditationJCI — Joint Commission International accreditation

Patients considering leukemia treatment can be cared for by Manipal Hospital, Old Airport Road's care team in Bangalore, India, from initial consultation through recovery. Manipal Hospital, Old Airport Road, accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing leukemia treatment.

4.5/5
Rating
1991
Established
680
Beds
Bangalore, India
Location
Enquire NowView Profile
Manipal Hospital Yeshwanthpur (Columbia Asia)

🇮🇳 Manipal Hospital Yeshwanthpur (Columbia Asia)

Yeshwanthpur, Bangalore, India 4.5 (98 reviews) 168 beds
Why consider this hospital?
4.5/5 rating from 98 reviews168 beds
Specialties & Accreditation
Cardiac SciencesOrthopedicsNeurosciencesOncologyGastroenterology
NABH — National Accreditation Board for Hospitals & Healthcare Providers accreditationJCI — Joint Commission International accreditation

Patients considering leukemia treatment can be cared for by Manipal Hospital Yeshwanthpur (Columbia Asia)'s care team in Yeshwanthpur, Bangalore, India, from initial consultation through recovery. Manipal Hospital Yeshwanthpur (Columbia Asia), accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing leukemia treatment.

4.5/5
Rating
2008
Established
168
Beds
Yeshwanthpur, Bangalore, India
Location
Enquire NowView Profile
Manipal Hospital Millers Road (Vikram Hospital)

🇮🇳 Manipal Hospital Millers Road (Vikram Hospital)

Millers Road, Bangalore, India 4.4 (74 reviews) 225 beds
Why consider this hospital?
4.4/5 rating from 74 reviews225 beds
Specialties & Accreditation
Cardiac SciencesOrthopedicsNeurosciencesOncologyGastroenterology
NABH — National Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering leukemia treatment can be cared for by Manipal Hospital Millers Road (Vikram Hospital)'s care team in Millers Road, Bangalore, India, from initial consultation through recovery. Manipal Hospital Millers Road (Vikram Hospital), accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing leukemia treatment.

4.4/5
Rating
2009
Established
225
Beds
Millers Road, Bangalore, India
Location
Enquire NowView Profile
Apollo Hospital, Bannerghatta Road

🇮🇳 Apollo Hospital, Bannerghatta Road

Bangalore, India 4.2 (25 reviews) 250 beds
Why consider this hospital?
4.2/5 rating from 25 reviews250 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
JCI — Joint Commission International accreditationNABH — National Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering leukemia treatment can be cared for by Apollo Hospital, Bannerghatta Road's care team in Bangalore, India, from initial consultation through recovery. Apollo Hospital, Bannerghatta Road, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing leukemia treatment.

4.2/5
Rating
2007
Established
250
Beds
Bangalore, India
Location
Enquire NowView Profile
Fortis Hospital, Bannerghatta Road

🇮🇳 Fortis Hospital, Bannerghatta Road

Bangalore, India 4.2 (58 reviews) 284 beds
Why consider this hospital?
4.2/5 rating from 58 reviews284 beds
Specialties & Accreditation
Multi SpecialtyCardiac SurgeryNeurosciencesOrthopedicsCancer
NABH — National Accreditation Board for Hospitals & Healthcare Providers accreditationJCI — Joint Commission International accreditation

Patients considering leukemia treatment can be cared for by Fortis Hospital, Bannerghatta Road's care team in Bangalore, India, from initial consultation through recovery. Fortis Hospital, Bannerghatta Road, accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing leukemia treatment.

4.2/5
Rating
2006
Established
284
Beds
Bangalore, India
Location
Enquire NowView Profile
Our Methodology

How we selected these hospitals

A hospital appears on this page when Hematology is among its listed specialties and it is located in Bengaluru, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.

What To Look For

How to Select the Best Hospital for Leukemia Treatment in Bengaluru, India?

Choosing the right hospital for leukemia treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:

International Accreditation

Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.

Specialization

Check that the hospital's listed specialties actually include hematology rather than only general care.

Capacity and Track Record

Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.

Transparent Costs

Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.

Clinical Overview

Understanding Leukemia Treatment

Leukaemia treatment in India and the UAE encompasses a full spectrum of evidence-based oncology protocols — including induction and consolidation chemotherapy, precision-targeted molecular therapies (TKIs, BCL-2 inhibitors), and allogeneic or autologous Bone Marrow Transplantation (BMT) — delivering complete remission rates of 70–90% for ALL and 60–80% for AML in adult patients at leading centres.

Chemotherapy cycles: 21–28 days per induction cycle (multiple cycles required); BMT (Bone Marrow Transplant): 30–45 days inpatient; Targeted therapy monitoring: 5–10 days initial admission
Hospital Stay
Chemotherapy-only patients: 4–6 weeks after cycle completion and haematological recovery; BMT patients: 90–120 days minimum post-transplant before international travel is medically safe; Targeted therapy patients: 3–4 weeks after dose stabilisation
Total Stay in Country (Fit-to-Fly)
Complete Remission Rate: 70–90% (ALL); 60–80% (AML); 5-year Overall Survival post-BMT: 50–70% depending on disease subtype, donor match, and remission status at transplant
Success Rate

Clinical Overview

  • Leukaemia is a malignancy of haematopoietic stem cells characterised by the clonal proliferation of immature or dysfunctional white blood cells within the bone marrow, peripheral blood, and lymphoid tissues.
  • The four principal subtypes — Acute Lymphoblastic Leukaemia (ALL), Acute Myeloid Leukaemia (AML), Chronic Lymphocytic Leukaemia (CLL), and Chronic Myeloid Leukaemia (CML) — differ substantially in their cytogenetic drivers, clinical behaviour, and therapeutic targets.
  • In ALL, chromosomal translocations such as the Philadelphia chromosome (BCR-ABL1 fusion, present in 25–30% of adult ALL) or MLL rearrangements dictate both prognosis and treatment selection.
Full details →

Who is a Candidate?

  • ELIGIBILITY — GENERAL: Adults and paediatric patients with a confirmed haematological malignancy diagnosis (bone marrow biopsy, flow cytometry, cytogenetics, and molecular profiling are mandatory prerequisites before any treatment consultation)
  • ACUTE LEUKAEMIA (ALL/AML): Newly diagnosed patients with ECOG performance status 0–2; patients with relapsed/refractory disease being evaluated for salvage therapy or transplant; patients who have failed 1–2 lines of prior therapy elsewhere seeking second-opinion protocol optimisation
  • CML: Patients in chronic phase intolerant or resistant to first- or second-generation TKIs; patients in accelerated or blast phase being considered for third-generation TKI (ponatinib, asciminib) bridging to allo-HSCT
  • CLL: Patients with del(17p) or TP53 mutation requiring BTK inhibitor (ibrutinib, acalabrutinib) or venetoclax-based therapy; Richter transformation requiring aggressive chemoimmunotherapy evaluation
  • +20 more

Treatment Options & Approaches

  • CHEMOTHERAPY PROTOCOLS Induction chemotherapy is the backbone of acute leukaemia management.
  • For AML, the '7+3' regimen (cytarabine 100–200 mg/m² continuous infusion × 7 days + daunorubicin or idarubicin × 3 days) remains the standard induction platform, with CPX-351 (liposomal cytarabine/daunorubicin) now preferred for therapy-related AML or AML with myelodysplasia-related changes.
  • For ALL, risk-stratified regimens such as hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with methotrexate and cytarabine) or BFM-based protocols are employed.

Recovery

  • PHASE 1 — PRE-ARRIVAL PREPARATION (2–4 WEEKS BEFORE TRAVEL) Step 1: GAF Healthcare receives all available medical records (bone marrow biopsy pathology, cytogenetics/NGS report, imaging, prior treatment history).
  • A senior haematologist/oncologist at the partner centre reviews the case and issues a detailed second-opinion report with recommended treatment protocol, estimated duration, and cost estimate within 48–72 hours.
  • Step 2: Patient and family complete the visa application.

Risks to be aware of

  • Leukaemia treatment, particularly intensive chemotherapy and allogeneic BMT, carries significant and well-characterised risks that patients and families must understand before committing to therapy.
  • During induction chemotherapy, the principal risks include febrile neutropaenia (occurs in >80% of AML induction patients), requiring prompt broad-spectrum IV antibiotics and antifungal escalation; tumour lysis syndrome (TLS), potentially causing acute renal failure, hyperkalaemia, and cardiac arrhythmias — mitigated by hyperhydration, allopurinol/rasburicase, and vigilant electrolyte monitoring; cardiotoxicity from anthracyclines (doxorubicin, idarubicin, daunorubicin), particularly cumulative cardiomyopathy with LVEF decline — monitored by serial echocardiography; and mucositis, hepatotoxicity, and neurotoxicity (vincristine-related peripheral neuropathy, high-dose methotrexate-related leukoencephalopathy).
Full details →

Why GAF Healthcare

  • GAF Healthcare provides a fully integrated, non-medical support infrastructure designed to eliminate logistical barriers for international patients and their families throughout the entire treatment journey.

Common questions about Leukemia Treatment

What is the cost of Leukaemia Treatment in India – Chemotherapy, Targeted Therapy & BMT in India vs UAE?
The total cost of leukaemia treatment varies significantly based on the specific treatment modality, number of chemotherapy cycles, disease subtype, and whether a Bone Marrow Transplant (BMT) is required. In India, at JCI- and NABH-accredited centres such as Tata Memorial Hospital (Mumbai), AIIMS (Delhi), Fortis Memorial Research Institute (Gurugram), Apollo Hospitals, or Manipal Hospitals, estimated costs are as follows: - Chemotherapy (induction + 1–2 consolidation cycles): USD 12,000 – USD 22,000 - Targeted therapy initiation and monitoring (e.g., TKI for CML, venetoclax-based regimen): USD 8,000 – USD 18,000 (excluding ongoing monthly drug costs) - Autologous BMT: USD 18,000 – USD 28,000 - Allogeneic BMT (matched sibling or unrelated donor): USD 28,000 – USD 55,000 These costs typically include hospital admission, chemotherapy drug administration, blood product support, infection prophylaxis, bone marrow biopsy, standard nursing in HEPA-filtered BMT rooms, and haematologist fees. CAR-T cell therapy, where available, carries additional manufacturing costs. In the UAE, at JCI- and DHA/MOHAP-licensed centres such as Cleveland Clinic Abu Dhabi, Burjeel Medical City, American Hospital Dubai, or Mediclinic City Hospital (Dubai), estimated costs are approximately 60–80% higher: - Chemotherapy (induction + consolidation): USD 28,000 – USD 50,000 - Targeted therapy initiation and monitoring: USD 20,000 – USD 40,000 - Autologous BMT: USD 45,000 – USD 65,000 - Allogeneic BMT: USD 65,000 – USD 110,000 The UAE premium reflects higher hospital infrastructure costs, luxury single-room accommodation, and broader multi-language concierge services. For patients from the Gulf Cooperation Council, East Africa, or Europe, the reduced travel burden may justify the higher cost. GAF Healthcare provides personalised cost estimates for each patient's specific protocol after case review, with no hidden charges.
How long do I need to stay in the country before I am fit to fly home after Leukaemia Treatment?
The minimum in-country stay before safe international travel (fit-to-fly clearance) depends critically on which treatment pathway is undertaken: CHEMOTHERAPY-ONLY (Induction ± Consolidation): Patients receiving induction chemotherapy (e.g., '7+3' for AML, hyper-CVAD Cycle 1A for ALL) must remain in-country for the full induction admission (21–28 days) plus post-nadir recovery. Fit-to-fly clearance is typically issued 4–6 weeks after the completion of each cycle, once the absolute neutrophil count (ANC) has recovered to >1.0 × 10⁹/L, platelet count is >50 × 10⁹/L, there is no active infection, and the patient is clinically stable. Patients requiring multiple consolidation cycles will need to either remain in-country between cycles or return for each cycle — a factor GAF Healthcare discusses during treatment planning so the patient's schedule and visa are managed accordingly. TARGETED THERAPY (TKIs, Venetoclax, BTK Inhibitors): For patients initiated on targeted oral therapies (e.g., imatinib/dasatinib for CML, venetoclax ramp-up for AML/CLL), the initial in-country stay for dose titration, toxicity monitoring, and response assessment is typically 3–4 weeks. Fit-to-fly clearance is issued once the patient has reached their maintenance dose without significant adverse events and has been educated on drug administration, monitoring parameters, and emergency contact protocols. Ongoing therapy is continued at home with periodic telemedicine review. BONE MARROW TRANSPLANT (Allogeneic or Autologous HSCT): This is the longest pathway. Patients must plan for a minimum 90 days in-country post-transplant (Day 0). The critical early post-transplant period (Day 0 to Day +100) requires: - Weeks 1–4: Inpatient in the BMT unit for engraftment, infection monitoring, GVHD prophylaxis, and transfusion support - Weeks 5–16: Daily to twice-weekly outpatient clinic attendance (must reside within 30–60 minutes of the transplant centre) for CBC, drug levels, CMV/EBV surveillance, and GVHD assessment - Day +100 evaluation: Bone marrow assessment and chimerism analysis to determine response and further management Fit-to-fly after BMT requires: confirmed full engraftment, ANC >1.0 × 10⁹/L without G-CSF, no active acute GVHD (Grade II or above), no active systemic infection, patient fully educated on immunosuppression regimen and emergency protocols, and explicit written medical clearance from the transplant physician. In straightforward, uncomplicated allogeneic BMT with MSD, this typically occurs between Day +90 and Day +120. Complicated transplants (GVHD, infections, slow engraftment) may require 5–6 months in-country. GAF Healthcare helps families plan long-stay accommodation, attendant visas, and financial logistics for the full required duration.
What is the success rate of Leukaemia Treatment with Chemotherapy, Targeted Therapy, and BMT?
Outcomes in leukaemia treatment are highly subtype-specific, risk-stratified, and influenced by disease biology, patient age, performance status, and the expertise of the treating centre. The following evidence-based benchmarks reflect outcomes achieved at high-volume, internationally accredited centres in India and the UAE that are partnered with GAF Healthcare: ACUTE MYELOID LEUKAEMIA (AML): - Complete Remission (CR) after induction chemotherapy: 60–80% of patients achieve morphological CR after one '7+3' induction cycle; a second induction achieves CR in an additional 10–15% - 5-year Overall Survival (OS) — Favourable risk (CBF-AML, NPM1-mutated without FLT3-ITD): 50–70% with chemotherapy alone - 5-year OS — Intermediate risk: 35–50%; Adverse risk (TP53, complex karyotype, FLT3-ITD high allelic ratio): 15–25% with chemotherapy alone, improved to 30–45% with allogeneic BMT in CR1 - Allogeneic BMT in CR1 (Intermediate/Adverse risk): 5-year DFS of 40–55% - Venetoclax + Azacitidine (unfit patients): CR/CRi rate 66%; Median OS 14.7 months vs. 9.6 months with azacitidine alone (VIALE-A trial) ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL): - Complete Remission after induction: 85–95% in adults - 5-year OS — Standard risk ALL: 50–65%; High-risk ALL: 30–50%; Ph+ ALL (with TKI + chemotherapy): 40–55% - Paediatric ALL (all risk groups): Event-Free Survival of 85–90% with modern BFM-based protocols - Blinatumomab for MRD+ ALL: MRD negativity achieved in 78% of patients; associated with improved OS vs. chemotherapy alone - Allogeneic BMT in CR2 (relapsed ALL): 5-year DFS 30–45% - CAR-T (tisagenlecleucel, paediatric/young adult R/R ALL): Overall remission rate 81%; 12-month EFS 50% in pivotal ELIANA trial CHRONIC MYELOID LEUKAEMIA (CML): - Major Molecular Response (MMR, BCR-ABL1 ≤0.1% IS) at 12 months with first-line TKI: 70–75% (imatinib), 76–80% (dasatinib/nilotinib), 82–87% (asciminib as second-line) - Treatment-Free Remission (TFR) — eligible patients after sustained deep molecular response (MR4.5): ~50% maintain remission off TKI - 10-year OS in CP-CML on TKI therapy: >85%, approaching normal life expectancy in optimal responders CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): - Progression-Free Survival (PFS) with venetoclax + obinutuzumab (CLL14 trial): 5-year PFS 62% vs. 27% with chlorambucil + obinutuzumab - Acalabrutinib-based regimens in relapsed/refractory CLL: 2-year PFS ~80% - Ibrutinib as first-line CLL (RESONATE-2): 7-year PFS 59%; OS 78% IMPORTANT CONTEXT: These success rates represent population-level data from clinical trials and registry analyses. Individual outcomes depend on accurate molecular risk stratification, MRD-guided treatment adaptation, transplant centre volume, and post-treatment monitoring compliance. GAF Healthcare's partner centres publish their own institutional transplant outcome data and are registered with national and international registries (EBMT, CIBMTR, NMDP). During your initial consultation, the treating haematologist will provide a personalised prognosis estimate based on your specific cytogenetics, molecular profile, performance status, and treatment history.

Related pages

How GAF Healthcare Assists in Choosing the Best Hospital for Leukemia Treatment in Bengaluru, India

Discover the Top Hospitals for Leukemia Treatment in Bengaluru, India

This page lists 10 accredited hematology hospitals in Bengaluru, India, so you can compare accreditation, specialties and bed capacity in one place.

Support When You Need It Most

Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.

Transparent, All-Inclusive Costs

We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.

Visa, Travel and Stay Coordination

Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.

Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.

Patient Success Story

Iraqi Family's Journey: Baby Ibrahim's Life-Saving Heart Surgery in India
Common Questions

Frequently asked questions about leukemia treatment in Bengaluru, India

How many hematology hospitals are listed in Bengaluru, India?
10 hospitals in our Bengaluru, India directory are currently listed for hematology including Leukemia Treatment.
How do you choose which hospitals to list?
A hospital appears on this page when Hematology is among its listed specialties and it is located in Bengaluru, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How much does treatment cost in India?
Cost varies by hospital, city and individual case. Use our cost calculator for a personalized estimate — see the link on this page.
Are there hematology hospitals for this in other India cities?
See the "Hospitals in other cities" links on this page for the full India list.
Are these hospitals internationally accredited?
Hospitals listed on this page carry accreditations including NABH, JCI, NABL, ISO 9001 — see the accreditation badge shown for each hospital below.
Can I get a treatment plan and cost estimate before I travel?
Yes. Share your medical reports with the GAF Healthcare team over WhatsApp or email, and our medical team will review them and come back with a recommended hospital, a treatment plan and an itemised cost estimate before you commit to anything.
Do you help with visa, travel and accommodation?
Yes. Once you choose a hospital, our team helps arrange the medical visa invitation letter, book accommodation near the hospital, and organise airport pickup and transport to appointments.
What support do I get during and after treatment?
Our medical team reviews your reports and stays in touch throughout your treatment journey — from the first consultation through recovery, including after you return home.
What does the "Featured" label next to a hospital's name mean?
"Featured" reflects editorial prominence on this listing, not a clinical ranking or a claim that it is the "best" hospital.
How do I get matched with the right hospital for leukemia treatment?
Share your medical reports and requirements with the GAF Healthcare team, and our medical coordinators will recommend a suitable hospital from this list based on your case.
Does the listed cost cover everything?
The figures shown are an indicative planning estimate, not a final quote from a specific hospital. Our team provides a single, itemised, all-inclusive quote before you make any commitment.
🤔

Still have questions?

Our coordinators are here to answer your questions about leukemia treatment in Bengaluru, India.

Next Step

Share your medical reports with us and our team will recommend a hospital and treatment plan for leukemia treatment in Bengaluru, India.

Contact us to report an inaccuracy on this page.

WhatsApp Us